Abstract: The present invention relates to pharmaceutical composition comprising GLP-1 analogue its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates thereof. The present invention further relates to a liquid composition comprising GLP-1 analogue or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates thereof, processes for preparing the composition and methods of using it. More particularly, the present invention relates to a liquid composition comprising Liraglutide, Semaglutide, D-Liraglutide, D-Semaglutide or other GLP-1 analogue thereof, processes for preparing the composition and methods of using it.
| # | Name | Date |
|---|---|---|
| 1 | 202147046993-STATEMENT OF UNDERTAKING (FORM 3) [14-10-2021(online)].pdf | 2021-10-14 |
| 2 | 202147046993-POWER OF AUTHORITY [14-10-2021(online)].pdf | 2021-10-14 |
| 3 | 202147046993-FORM 1 [14-10-2021(online)].pdf | 2021-10-14 |
| 4 | 202147046993-DRAWINGS [14-10-2021(online)].pdf | 2021-10-14 |
| 5 | 202147046993-DECLARATION OF INVENTORSHIP (FORM 5) [14-10-2021(online)].pdf | 2021-10-14 |
| 6 | 202147046993-COMPLETE SPECIFICATION [14-10-2021(online)].pdf | 2021-10-14 |
| 7 | 202147046993.pdf | 2021-10-23 |
| 8 | 202147046993-Proof of Right [11-11-2021(online)].pdf | 2021-11-11 |
| 9 | 202147046993-FORM-26 [22-02-2022(online)].pdf | 2022-02-22 |
| 10 | 202147046993-FORM 3 [22-02-2022(online)].pdf | 2022-02-22 |
| 11 | 202147046993-FORM 18 [05-04-2023(online)].pdf | 2023-04-05 |
| 12 | 202147046993-FER.pdf | 2023-11-17 |
| 1 | search(1)E_16-11-2023.pdf |